June 2016 in “CRC Press eBooks” Sleep problems and skin issues affect each other; poor sleep can worsen skin conditions, and some skin treatments can improve or harm sleep quality.
1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
31 citations
,
July 2017 in “Journal of the American Academy of Dermatology” Apremilast improved symptoms in patients with severe skin conditions.
26 citations
,
March 2015 in “American journal of clinical dermatology” Topical clobetasol is recommended over mycophenolate mofetil for treating Lichen Planopilaris due to better safety and patient satisfaction.
Antifungal treatment reduced asthma exacerbations and corticosteroid use but its overall benefit is unclear.
7 citations
,
June 2010 in “Journal of The American Academy of Dermatology” Tranilast successfully treated a man's skin sarcoidosis when other treatments failed.
19 citations
,
April 2014 in “Veterinary Dermatology” Demodicosis should be considered in cats with facial skin issues exposed to inhalant glucocorticoids.
13 citations
,
April 2020 in “European Journal of Dermatology” Apremilast showed mixed results for treating severe alopecia areata.
February 2023 in “Reactions Weekly”
20 citations
,
March 2020 in “Journal of Asthma” Older adults can also get asthma.
1 citations
,
September 2022 in “Nepal journal of dermatology, venereology & leprology” Apremilast shows promise for several skin conditions but needs more research.
July 2003 in “Pediatrics in review” In 2001, the FDA approved 12 new drugs for children to treat allergies, asthma, ADHD, birth control, and other conditions.
1 citations
,
April 2024 in “Skin research and technology” Topical rosuvastatin and melatonin creams significantly reduce psoriasis severity and are safe.
October 2023 in “Naunyn-Schmiedeberg's Archives of Pharmacology” Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
14 citations
,
November 2016 in “Lupus” Lenalidomide effectively and safely treats skin symptoms in pediatric lupus, reducing the need for prednisone.
4 citations
,
January 2023 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
79 citations
,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
October 2015 in “Elsevier eBooks” Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.
8 citations
,
March 2018 in “Expert Review of Respiratory Medicine” Inhalation therapy may repair and protect elastin in the lungs of COPD patients.
70 citations
,
February 2018 in “Seminars in Arthritis and Rheumatism” Belimumab reduces disease activity, steroid use, and flares in lupus patients.
42 citations
,
November 2018 in “Archives of dermatological research” Apremilast was not effective in treating moderate-to-severe alopecia areata.
9 citations
,
September 2010 in “Dermatologic therapy” Combining cetirizine and topical steroids can effectively manage severe lichen planus pilaris.
13 citations
,
November 2021 in “Pediatric Dermatology” Tofacitinib taken by mouth helps treat hair loss in children.
1 citations
,
December 2022 in “Journal of cosmetic dermatology” The combination of vitamin D analogues with potent steroids is a favorable treatment for alopecia areata with fewer side effects.
1 citations
,
March 2024 in “BioDrugs” Biologics for severe asthma have known side effects, but some new risks need more study.
April 2023 in “Journal of Investigative Dermatology” The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.